OICHARTS
8 AMThe 8 AM report →

HALO

Halozyme Therapeutics, Inc. · XNAS · 131 sessions on record
$110.40▼ −1.16 · −1.0%from $111.56 the session before · Sep 30, 2026 close · end of day
Open
$111.54
High
$112.45
Low
$110.35
Day's range
$2.11.9% of the previous close
VWAP
$110.72close −0.29% from it
Volume, shares
3.52M1.50× the 20-session average
Traded, $
$389.9M
Trades
21.9K160 shares per trade
Previous close
$111.56−1.16 to the close
Market cap
$12.53Bat the close of Sep 30
Day range2% of the way up
$110.35$112.45
52-week range88% of the way up
$61.33 Mar 27$116.85 Sep 23

−5.5% from the high · +80% from the low

Options

No listed options on HALO

Close $ · S&P 500 rebased to the first close126 sessions to Sep 30 · axis fixed at 4 × ATR-14 around the last close
131 sessions on file · from Mar 25
HALO close over the last 126 sessions, with S&P 500 rebased to the first close63.0692.91122.76axis spans 95%S&P 500HALOApr 1Jul 2Sep 30126 sessions from Apr 1 to Sep 30; the price axis spans 95 percent.

Quarterly results

consolidated · latest filed Aug 6, 2026 · SEC filings

Revenue $481.0M, +48% on a year earlier; profit $229.9M, +39% in the Jun 2026 quarter, consolidated.

Last 8 quarters, consolidatedUS dollars as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, S&P 500 over the same session
Quarterly results of HALO on the consolidated basis with the market's move on the first session after each filing
QuarterRevenue $Revenue YoYProfit $Profit YoYEPS $Market on the day
Jun 2026filed Aug 6$481.0M▲ +48%$229.9M▲ +39%1.90▲ +20.2%S&P 500 +0.6% · +19.6 pp
Mar 2026filed May 11$376.7M▲ +42%$150.0M▲ +27%1.22▲ +6.8%S&P 500 −0.2% · +7.0 pp
Dec 2025filed Feb 17$451.8M▲ +52%−$141.6M▼ −200%-1.13—not reached
Sep 2025filed Nov 3$354.3M▲ +22%$175.2M▲ +28%1.43—not reached
Jun 2025filed Aug 6$325.7M▲ +41%$165.2M▲ +77%1.33▲ +20.2%S&P 500 +0.6% · +19.6 pp
Mar 2025filed May 11$264.9M▲ +35%$118.1M▲ +54%0.93▲ +6.8%S&P 500 −0.2% · +7.0 pp
Dec 2024filed Feb 18$298.0M▲ +30%$137.0M▲ +60%1.06—not reached
Sep 2024filed Nov 3$290.1M▲ +34%$137.0M▲ +67%1.05—not reached
By fiscal yearfiscal years as filed in the 10-K · named by the year the fiscal year ends
Financial-year results of HALO on the consolidated basis, summed from the quarters filed
YearRevenue $Revenue YoYProfit $Profit YoYEPS $
FY25to Dec 2025$1.40B▲ +38%$316.9M▼ −29%2.56
FY24to Dec 2024$1.02B▲ +22%$444.1M▲ +58%3.43
FY23to Dec 2023$829.3M▲ +26%$281.6M▲ +39%2.10
FY22to Dec 2022$660.1M▲ +49%$202.1M▼ −50%1.44
FY21to Dec 2021$443.3M▲ +66%$402.7M▲ +210%2.74

Fundamentals

consolidated · filings to Jun 2026 · close $110.40 on Sep 30

HALO trades at 32 times trailing earnings, 87 times book value, revenue +41% over twelve months, market cap $12.53B.

Valuation
Market cap
$12.53Bon Sep 30
Price to earnings
32consolidated · four quarters to Jun 2026
Trailing EPS
$3.42diluted · consolidated · four quarters to Jun 2026
Price to book
87consolidated · balance sheet to Jun 2026
Book value a share
$1.26consolidated · balance sheet to Jun 2026
Debt to equity
—
Return on equity
170%trailing profit over average equity · consolidated
Dividend yield
—
Price to sales
7.5market cap over revenue, four quarters to Jun 2026
Shares outstanding
113Mon Sep 30
Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated
Revenue, trailing 12 months
$1.66Bfour quarters to Jun 2026
Revenue growth, 12 months
▲ +41%against the twelve months before
Revenue 3-year CAGR
▲ +29%trailing twelve months against the twelve months 3 years earlier · consolidated
Profit, trailing 12 months
$413.6Mfour quarters to Jun 2026
Profit growth, 12 months
▼ −26%against the twelve months before
Profit 3-year CAGR
▲ +21%trailing twelve months against the twelve months 3 years earlier · consolidated
PeersBiological Products, (No Diagnostic Substances) · the ten largest by market cap · industry P/E needs two stocks with trailing profit and a market cap
Stocks in the industry Biological Products, (No Diagnostic Substances) with market cap, price to earnings and price to book
StockMarket capP/EP/BClose $
MRNAModerna, Inc. Common Stock$76.88Bon Sep 30—11$192.57
HALOHalozyme Therapeutics, Inc.$12.53Bon Sep 3032consolidated87$110.40
TECHBio-Techne Corp.$11.36Bon Sep 3062consolidated5.4$72.47
KODKodiak Sciences Inc Common Stock$5.96Bon Sep 30—98$94.80
ALLOAllogene Therapeutics, Inc. Common Stock$552.8Mon Sep 30—1.3$1.60
DTILPrecision BioSciences, Inc. Common Stock$172.8Mon Sep 30—3.8$6.26
OTLKOutlook Therapeutics, Inc. Common Stock$139.6Mon Sep 30——$0.57
BSEMBioStem Technologies, Inc. Common Stock$55.2Mon Sep 30—2.0$3.09
TVGNTevogen Inc. Common Stock$43.1Mon Sep 30——$6.62
BCDABioCardia, Inc. Common Stock$15.3Mon Sep 30—5.7$1.01

Shareholding

quarter to Jun 2026 · SEC Form 13F

13F managers hold 210% of shares, BlackRock, Inc. the largest at 23%, VANGUARD CAPITAL MANAGEMENT LLC 9.4% and VANGUARD PORTFOLIO MANAGEMENT LLC 9.3%, as filed for the quarter to Jun 2026.

Held by 13F managers
210%of shares outstanding
Shares held
237M−0.23% on Mar 2026 among managers filing both
Managers holding
615585 a quarter earlier
Largest holder
23%BlackRock, Inc.
Largest 10 holderspercent of shares outstanding · change in shares against the previous quarter
Largest 13F holders of HALO
ManagerSharesOf outstandingValueChange on quarter
BlackRock, Inc.26.5M23%$2.08B+12.1K
VANGUARD CAPITAL MANAGEMENT LLC10.7M9.4%$837.7M+160K
VANGUARD PORTFOLIO MANAGEMENT LLC10.6M9.3%$829.5M+99.6K
STATE STREET CORP10.4M9.1%$810.8M+483K
Invesco Ltd.6.36M5.6%$497.5M−1.67M
MORGAN STANLEY5.67M5.0%$443.4M+541K
Boston Partners5.55M4.9%$433.6M+180K
BANK OF AMERICA CORP /DE/5.48M4.8%$429.0M−345K
GEODE CAPITAL MANAGEMENT, LLC5.04M4.4%$394.6M+28.3K
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC5.02M4.4%$393.1M−29.9K
Insider tradesSEC Forms 3, 4 and 5 · the latest 10

No open-market insider buying or selling in the last 90 days.

HALO insider trades
InsiderTradeSharesPriceHeld after
Krishnan MaheshDirectorexercised · Jun 29, 20267,304$38.4621,766
Krishnan MaheshDirectorsold · Jun 29, 20267,304$75.0014,462
Snyder Mark HowardOfficerwithheld for tax · Jun 12, 20262,715$69.5049,929
Snyder Mark HowardOfficerexercised · Jun 12, 20265,034$0.0052,644
Torley HelenDirector,Officersold · Jun 3, 20266,100$69.69767,780
Torley HelenDirector,Officersold · Jun 2, 20263,400$66.75767,780
Torley HelenDirector,Officerexercised · Jun 3, 202610,000$12.07777,780
Torley HelenDirector,Officerexercised · Jun 1, 202620,000$12.07787,780
Torley HelenDirector,Officersold · Jun 1, 20261,610$66.39786,170
Torley HelenDirector,Officersold · Jun 1, 202612,989$67.41773,181

Corporate actions

exchange records

No corporate action on record for HALO yet.

Price history

131 sessions on record · to Sep 30 · end of day

HALO is +2.5% over 20 sessions against the S&P 500's +0.1%, 5.5% below its 52-week high, realised volatility 26% annualised.

Returns against S&P 500longest window first · S&P 500 over the same sessions
Returns of the stock and S&P 500 over six windows, longest first
WindowFrom $HALO %S&P 500 %Difference pp
120 sessionssince Apr 9$67.08▲ +65%▲ +12%+52
60 sessionssince Jul 7$81.57▲ +35%▲ +2.0%+33
20 sessionssince Sep 1$107.72▲ +2.5%▲ +0.11%+2.4
5 sessionssince Sep 23$112.44▼ −1.8%▼ −0.67%−1.1
1 sessionsince Sep 29$111.56▼ −1.0%▼ −0.21%−0.83
Averages of the closeclose against each average
5-session average
$112.79close −2.1% from it
20-session average
$110.41close −0.01% from it
50-session average
$101.77close +8.5% from it
Range and volumetrue range over 14 sessions · high to low over 20 · volume against the 20-session average
Average true range, 14
$3.12.8% of the close
Average day's range, 20
$3.02.7% of the close
Volume against 20 sessions
1.50×3.52M vs 2.48M average
Volatility and co-movement with S&P 500annualised from daily returns
Realised volatility, 20
26%≈ ±1.6% a session · moved more than that on 7 of 20
Realised volatility, 60
46%≈ ±2.9% a session · moved more than that on 5 of 60
Beta to S&P 500, 60
0.25moved with S&P 500 on 32 of 60 sessions
Up and down sessionscloses above and below the previous close
Last 20 sessions
9 up · 11 downof 20
Last 60 sessions
29 up · 30 downof 59
Best session, 250
▲ +20%Aug 7
Worst session, 250
▼ −3.1%Jul 10

Short-sale volume

25 sessions · to Sep 30, 2026

Short sales were 66% of reported volume on Sep 30, 2026, against 55% over the last 25 sessions.

Last 10 sessionsshare of the day's reported volume
HALO daily short-sale volume
SessionShort volumeReported volumeShort share
Sep 30, 2026838K1.27M66.1%
Sep 29, 2026346K685K50.5%
Sep 28, 2026580K830K69.8%
Sep 25, 2026964K1.23M78.4%
Sep 24, 2026888K1.51M58.7%
Sep 23, 20261.06M1.66M63.6%
Sep 22, 20261.62M2.15M75.2%
Sep 21, 20261.33M1.78M74.6%
Sep 18, 20266.43M6.97M92.3%
Sep 17, 2026327K716K45.6%

Filings

SEC EDGAR · newest first
HALO SEC filings
FiledFormReport date
Sep 30, 20268-KSep 28, 2026
Sep 22, 20268-KSep 22, 2026
Sep 18, 20268-KSep 17, 2026
Sep 17, 20264Sep 16, 2026
Sep 16, 2026144—
Sep 16, 20268-KSep 16, 2026
Sep 11, 20264Sep 9, 2026
Sep 2, 20264Sep 1, 2026
Aug 21, 20263Aug 14, 2026
Aug 19, 20264Aug 17, 2026
Aug 18, 20268-KAug 14, 2026
Aug 17, 2026144—
Aug 11, 2026144—
Aug 11, 20264Aug 10, 2026
Aug 10, 2026144—
Aug 6, 202610-QJun 30, 2026
Aug 6, 20268-KAug 6, 2026
Jul 9, 20264Jul 8, 2026
Jul 2, 20264Jun 30, 2026
Jul 2, 20264Jul 1, 2026
Jul 2, 20264Jul 1, 2026
Jul 2, 20268-KJun 30, 2026
Jun 30, 20264Jun 29, 2026
Jun 29, 2026144—
Jun 15, 20264Jun 12, 2026

About Halozyme Therapeutics, Inc.

SEC and exchange records
Company
Halozyme Therapeutics, Inc.
Exchange
XNAS
Industry
Biological Products, (No Diagnostic Substances) · SEC standard industrial classification
SEC CIK
1159036
Sessions on record
131
Price source
End of day · delayed
Computed
1 Oct, 10:42 pm IST

OI Charts is not a registered investment adviser or broker-dealer. Prices, filings and open interest are public data and arithmetic on it, not a basis for any investment decision.